Project Grant 2112383
Award Date 7/1/21
Completion Date 12/31/21
Dollars Obligated $256K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92101, USA
Similar Awards
- This SBIR Phase I project awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program seeks to develop a new class of gene therapies that can be delivered more safely, cost-effectively, and at scale for a wide range of serious genetic disorders. The project leverages short oligonucleotides conjugated with small molecules to induce proximity of endogenous epigenetic machinery to disease-relevant genes in a precise and reversible...
- Altigg Therapeutics, Inc. was awarded a $255,595 Small Business Technology Transfer (STTR) Phase I Project Grant from the National Science Foundation's Engineering program (CFDA 47.041) for the period of April 1, 2021 through March 31, 2022. Under this award, Altigg Therapeutics will develop a platform for the rapid discovery of human antibodies as therapeutics for infectious diseases such as COVID-19. The NSF Engineering program seeks to improve quality of life and economic strength through...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant provides $303,445 to Endura Therapeutics Inc. to develop a next-generation sequencing platform for discovering small molecules that target RNA. The project aims to demonstrate that small molecules can modulate protein expression by binding to messenger RNA and to create a high-throughput screening method to identify such molecules and their optimal RNA targets. If successful, this work...
- This Project Grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) provides $275,000 to Altay Therapeutics, Inc., a biotechnology company, to develop novel small molecule therapies that target disease-causing transcription factors for treating chronic illnesses and cancers. The key goals of this SBIR Phase I project are to: (1) determine the toxicity profile of new inhibitors across human cells, (2) measure drug specificity to the target...
- Stellate DNA LLC received a $256,000 National Science Foundation Project Grant under the NSF Technology, Innovation, and Partnerships program to develop a novel class of molecular vehicles for the targeted and precise integration of specified genetic information into the genomes of host cells and organisms. The one-year award runs from July 2021 through November 2022 and supports research to advance science and engineering leading to breakthrough technologies and solutions to national...
- The National Science Foundation (NSF) awarded a $275,000 Project Grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Foragr Medicines, Inc. for a SBIR Phase I project titled "High-Throughput Platform for Small Molecule, In-Cell Targeting of Undruggable Proteins via their mRNAs". The project aims to develop a high-throughput drug discovery platform to identify small molecule drugs that can target the mRNA of hard-to-treat diseases, including...
- Talus Bioscience Inc. received a $255,831 Small Business Innovation Research Phase I Project Grant from the National Science Foundation under the Engineering (47.041) federal assistance program. The grant funds research to develop simultaneous in situ pharmacological profiling technologies for gene regulatory proteins involved in cancer therapy. Specifically, Talus Bioscience will work to profile multiple gene regulatory proteins and their functional interactions within intact biological systems...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) award of $274,947 to Lattice Therapeutics Inc. supports the development of a customizable, next-generation RNA delivery particle. The project aims to validate the ability of an engineerable protein nanoparticle platform to efficiently and specifically deliver RNA cargoes to target cancer cells. Key objectives include in vitro evaluation of RNA...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 provides funding to Clue Genetics Inc. for the development of a fungi-focused metabologenomics platform for natural product discovery. The key products and services to be delivered under this 1-year Phase I SBIR project include: Annotating biosynthetic gene clusters (BGCs) from 200 genomes selected from a diverse set of bioactive fungi to uncover new drugs,...
- The National Science Foundation awarded Sarkar-Klein-Labs, LLC a $225,000 Project Grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to support the STTR PHASE I: PROTEASE-BASED PURIFICATION OF RECOMBINANT HUMAN MATRIX METALLOPROTEASES project. This two-year project beginning February 1, 2021 aims to develop protease-based purification methods for recombinant human matrix metalloproteases, which are enzymes involved in tissue remodeling and disease processes. The...